Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30735834 | 0.91 | HTR2C (0.49) | HTR6GABRA1GABRB2IRAK4HTR2C | |
| SCHEMBL7963921 | 0.91 | HTR2C (0.49) | HTR6GABRA1GABRB2IRAK4HTR2C | |
| SCHEMBL13728399 | 0.80 | CYP11B2 (0.42) | IRAK4 | |
| SCHEMBL28442398 | 0.77 | TDP1 (0.41) | — | |
| Cyclohexane SCHEMBL22288135 | 0.76 | TDP1 (0.44) | — | |
| SCHEMBL11665783 | 0.76 | TDP1 (0.44) | — | |
| SCHEMBL19284583 | 0.74 | PRKCZ (0.48) | HTR2C | |
| SCHEMBL30368871 | 0.74 | PRKCZ (0.48) | HTR2C | |
| SCHEMBL7963306 | 0.73 | MAPK1 (0.40) | — | |
| SCHEMBL2710242 | 0.72 | HTR2C (0.56) | HTR6GABRA1HTR2CADRB2SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1315830-A | Method for treating anxiety disorders | LILLY CO ELI (US) | 2001-10-03 | — | — | CN | disclosed |
| US-6242450-B1 | SUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | disclosed |
| WO-2000006082-A2 | TREATMENT OF ANXIETY DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006166-A1 | 5-HT1F ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976746-A1 | 5-HT1F antagonists | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0976747-A2 | Use of 5HT-1F receptor antagonists for treating anxiety disorders | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |